144P First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Patients with squamous NSCLC have a poorer prognosis than those with non-squamous histology and fewer treatment options. The phase 3 EMPOWER-Lung 1 study (NCT03088540) has demonstrated significant survival benefits of first-line (1L) cemiplimab monotherapy vs chemotherapy and an acceptable safety profile in patients with treatment-naïve squamous or non-squamous NSCLC with PD-L1 expression ≥50% and no EGFR, ALK or ROS1 aberrations. Here, we report 5-year results of patients with squamous NSCLC from this study.
Authors
- Chen Zhu (ORCID: https://orcid.org/0000-0002-1002-8387)
- Igor Bondarenko (ORCID: https://orcid.org/0000-0002-7071-2471)
- S. Kilickap
- T. Melkadze
- T. Makharadze
- E. Kim
- A. Baramidze
- Heather Magnan (ORCID: https://orcid.org/0000-0003-2422-9769)
- J-F. Pouliot
- Atakan Sezer (ORCID: https://orcid.org/0000-0002-2846-6879)
- F. Seebach
- K.D. Penkov
- M. Ozguroglu
- M. Gogishvili
- E. Kalinka
Institutions
- Regeneron (United States) (US)
- Başkent University (TR)
- Istanbul University-Cerrahpaşa (TR)
- Istinye University (TR)
- Polish Mother’s Memorial Hospital Research Institute (PL)
- Istanbul Medeniyet University (TR)
- Tbilisi State Medical University (GE)
- Dnipro State Medical University (UA)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100773
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00